Clinicians Are Rethinking How They Treat the Hardest Cases of Depression
A new analysis published in Psychiatric Times this month examines how clinicians are approaching treatment-resistant depression (TRD) — a condition affecting an estimated 30% of people diagnosed with major depressive disorder who do not respond adequately to two or more antidepressant trials. The piece highlights a growing clinical consensus around rapid-acting, glutamatergic interventions, with esketamine (brand name Spravato) emerging as a front-line consideration for patients experiencing suicidal ideation or urgent depressive episodes.
The report underscores what many in the ketamine treatment space have observed firsthand: traditional antidepressants operate on the serotonergic system and can take weeks to produce results — an unacceptably long timeline for patients in crisis. Esketamine, an FDA-approved intranasal formulation of ketamine's S-enantiomer, works on NMDA glutamate receptors and can produce measurable improvements in mood within hours to days. For clinicians managing patients with active suicidal ideation, that speed differential is not a minor feature — it can be life-saving.
Patient Preferences and Access Barriers Are Shaping Treatment Decisions
One of the more clinically significant takeaways from the Psychiatric Times analysis is its focus on the human side of treatment selection. Clinicians aren't just weighing pharmacology — they're navigating a complex intersection of patient preferences, insurance coverage, geographic access, and the practical realities of in-office administration requirements.
Esketamine is currently required by the FDA to be administered in a certified healthcare setting under the REMS (Risk Evaluation and Mitigation Strategy) program. Patients must be monitored for at least two hours post-dose for dissociation, blood pressure changes, and sedation. This requirement, while important for safety, creates a meaningful logistical hurdle — particularly for patients in rural areas, those without reliable transportation, or those juggling work and caregiving responsibilities.
The analysis from Psychiatric Times notes that these access barriers are influencing how clinicians and patients alike are evaluating their options, with some turning to IV ketamine infusions or oral ketamine protocols — many of which are now available through telehealth platforms — as more flexible alternatives within the broader ketamine treatment ecosystem.
Key Takeaway for Patients
Esketamine (Spravato) and IV ketamine are related but distinct treatments. Esketamine requires in-person administration under clinical supervision due to FDA REMS requirements. If you're exploring ketamine-based care through a telehealth provider, you're most likely being evaluated for oral or sublingual ketamine — a different delivery method with its own evidence base. Understanding which treatment you're being offered, and why, is a critical question to ask before starting any program.
What This Means If You're Considering Online Ketamine Treatment
For patients researching ketamine therapy through telehealth channels, the growing clinical literature around esketamine reinforces several important points worth understanding before you begin the provider selection process.
Not all ketamine is the same. The term "ketamine treatment" covers a spectrum — IV infusions administered in a clinic, FDA-approved intranasal esketamine (Spravato) delivered in certified offices, and oral or sublingual ketamine protocols that telehealth providers can prescribe and ship to your home. Each has a different evidence profile, different safety monitoring requirements, and different cost structures. Reputable telehealth providers will be transparent about which modality they offer and why it may or may not be appropriate for your specific presentation.
Screening rigor matters more for complex cases. The Psychiatric Times analysis specifically addresses TRD and suicidal depression — the more severe end of the spectrum. If you're in this category, your intake screening should be thorough. A quality telehealth ketamine provider will conduct detailed psychiatric evaluations, review your medication history, and assess suicide risk before approving treatment. Be cautious of platforms that rush through intake or minimize the complexity of your history.
Follow-up care is where outcomes are made or lost. Rapid-acting treatments like ketamine produce quick results, but the durability of those results depends heavily on what happens after the acute phase. The clinical literature consistently points to the importance of integration support, therapy, and ongoing psychiatric oversight. When evaluating a telehealth ketamine provider, ask specifically about their follow-up protocols — how often you'll check in with a clinician, whether therapy coordination is offered, and how they handle cases where the initial treatment doesn't produce the expected response.
Out-of-pocket costs remain a barrier — but so does doing nothing. Esketamine via Spravato has achieved some insurance coverage, particularly for TRD, though prior authorization requirements remain burdensome. Telehealth oral ketamine programs are almost universally out-of-pocket, typically ranging from a few hundred to over a thousand dollars per month depending on the provider and protocol. That cost is real. But for patients who have cycled through multiple antidepressants without relief, the cost of continued treatment failure — in quality of life, lost productivity, and crisis-level care — deserves equal weight in that calculation.
The Broader Signal: Glutamatergic Treatments Are Entering the Mainstream
The fact that a publication like Psychiatric Times is running substantive clinical analysis on esketamine and TRD in 2026 reflects how significantly the field has shifted in the past decade. Ketamine-based treatments, once considered experimental or fringe, are now part of mainstream psychiatric practice guidelines. That normalization benefits patients — it means more providers are familiar with these options, more insurers are being pushed to cover them, and the stigma around seeking this type of care continues to erode.
For anyone who has struggled with depression that hasn't responded to standard treatments, that shift matters. The clinical momentum is real, the safety profile is well-documented when treatments are administered responsibly, and access — while still imperfect — is broader than it has ever been. The key is finding a provider whose standards match the seriousness of your situation. Read the full Psychiatric Times analysis here.
Share